Clinical Management of Epilepsy With Glutamic Acid Decarboxylase Antibody Positivity: The Interplay Between Immunotherapy and Anti-Epileptic Drugs

Frontiers in Neurology- Switzerland

doi 10.3389/fneur.2018.00579

Full Text

Abstract

Available in

Categories

Date

July 13, 2018

Authors

Kari-Matti Mäkelä

Publisher

Frontiers Media SA

Related search

Epilepsy and Cerebellar Ataxia Associated With Anti-Glutamic Acid Decarboxylase Antibodies

Journal of Neurology, Neurosurgery and Psychiatry

English

Clinical Characteristics of Anti-Glutamic Acid Decarboxylase Antibody-Positive Fulminant Type 1 Diabetes

Endocrine Journal

English

Cerebellar Ataxia With Anti–Glutamic Acid Decarboxylase Antibodies

Archives of Neurology

English

Diabetes Mellitus and Ataxia With Anti-Glutamic Acid Decarboxylase Antibodies

Endocrine Abstracts

English

Cerebellar Ataxia Associated With Glutamic Acid Decarboxylase Autoantibody (Anti GAD)

Scholars Journal of Medical Case Reports

English

Effects of Anti-Glutamic Acid Decarboxylase Antibodies Associated With Neurological Diseases

Annals of Neurology

English

The Role of Anti-Glutamic Acid Decarboxylase Autoantibodies in Mood Disorders

Neuroimmunology and Neuroinflammation

English

Epilepsy in Mice Deficient in the 65-kDa Isoform of Glutamic Acid Decarboxylase

Proceedings of the National Academy of Sciences of the United States of America

Multidisciplinary

English

Adherence and Persistence to Anti-Epileptic Drugs Among u.s. Veterans Diagnosed With Epilepsy

Value in Health

Occupational Health

English